The US Food and Drug Administration has expanded the use of Bristol-Myers Squibb Co's Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer, reports Reuters Health.
Opdivo, part of a new class of medicines designed to use the body's own immune system to fight cancer, is already approved to treat advanced melanoma, a form of lung cancer, kidney cancer, and Hodgkin lymphoma.
The report says the FDA is slated to decide in May whether to approve rival Merck & Co Inc's combination of immunotherapy Keytruda and chemotherapy for first-line lung cancer.
[link url="http://www.reuters.com/article/us-bristol-opdivo-fda-idUSKBN15H2O6"]Reuters Health report[/link]
[link url="http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm539646.htm"]FDA material[/link]